LETTER TO THE EDITOR

Guillain–Barré syndrome following Covid-19 immunization: a report of two cases

Francesco Bax1,2 · Gian Luigi Gigli1,2 · Enrico Belgrado1 · Laura Brunelli2,3 · Mariarosaria Valente1,2

Received: 3 June 2021 / Accepted: 6 September 2021 / Published online: 1 October 2021
© Belgian Neurological Society 2021

Keywords Guillain–Barré syndrome · Adverse event following immunization (AEFI) · AIDP · AMSAN · Covid-19 · Vaccine

To the Editor,

We hereby report two cases of GBS occurred within a population of 76,640 people who received either the first or second dose of one of the approved Covid-19 vaccines as of April 15th, 2021, in Udine province, Italy (current resident population 516,418 inhabitants). The first patient was a 90-year-old man, previously in good physical and mental conditions, who developed acute progressive gait imbalance three days after receiving the second dose of BNT162b2 vaccine. Electroneuromyography (ENMG) performed at three weeks from the onset of symptoms, showed signs of acute four limbs axonal sensory-motor polyneuropathy, while cerebrospinal fluid (CSF) analysis was normal. Acute motor sensory axonal neuropathy (AMSAN) was diagnosed according to the current electrophysiological criteria [1], the patient was admitted for clinical monitoring and intravenous immunoglobulins (ivIG) were administered. Serum autoimmunity revealed high titer anti-GQ1b and anti-titin antibodies. Considering anti-titin positivity, ENMG was repeated, excluding neuromuscular junction involvement and completion with thoracic computer tomography scan excluded thymoma. During his hospital stay, he remained clinically stable and was discharged home able to stand and walk with minor assistance. The second patient was a 51-year-old woman who developed distal limb paresthesias with new-onset sphincter disturbances and lumbar pain, ten days after receiving the first dose of ChAdOx1 nCoV-19 vaccine. ENMG examination showed F-wave conduction delay while CSF presented marked albumin-cytological dissociation. Acute inflammatory demyelinating polyneuropathy (AIDP) was diagnosed, the patient was admitted for clinical monitoring and ivIG were administered. During her hospital stay she developed facial diplegia, bilateral foot dorsiflexion weakness (MRC 4/5) and lower limbs areflexia. A whole spine magnetic resonance imaging was unremarkable. Serum autoimmunity, including search for anti-ganglioside antibodies, was negative. Distal limb neuropathic pain required introduction of analgesic therapy. The patient was discharged home able to walk unaided. Patients’ details are available in Table 1.

GBS is described as a complication following different kinds of vaccinations, and the Brighton Collaboration GBS Working Group has developed guidelines which are intended to help in reporting cases of GBS as adverse events following immunization and to harmonize vaccine safety reporting: in fact, GBS can be temporally associated with, but is not necessarily the result of the vaccine [2]. As regards Covid-19 immunization, a recent report from the Janssen Ad26.COV2.S vaccine trial has highlighted that GBS may occur in the context of the vaccination as well as in the placebo arm with the same incidence, supporting a casual role [3]. Concerning BNT162b2 and ChAdOx1 nCoV-19 vaccines instead, one case of GBS following the administration of each vaccine has been reported so far [4, 5]. Moreover, amid the global vaccination program, it is expected that many GBS cases would be identified by chance in the 10 weeks period following a double dose vaccination and that this association cannot be considered a causal link [6].

GBS has also been extensively reported after Covid-19 infection: AIDP is the most common form, but acute motor

---

Francesco Bax
bax.francesco@spes.uniud.it

1 Clinical Neurology, Udine University Hospital, Piazza S. Maria della Misericordia 15, 33100 Udine, Italy
2 Department of Medicine, University of Udine, Udine, Italy
3 Accreditation and Quality Unit, Udine University Hospital, Udine, Italy
Table 1  Clinical characteristics of patients with GBS

|                        | Patient #1                        | Patient #2                        |
|------------------------|-----------------------------------|-----------------------------------|
| **Sex**                | Male                              | Female                            |
| **Age**                | 90 years old                      | 51 years old                      |
| **Medical history**    | Arterial hypertension, chronic kidney disease, psoriasis, previous gastric resection, and prostatesctomy | Unremarkable                      |
| **Preceding triggering events*** | None reported                     | None reported                     |
| **Interval of symptoms onset after vaccine first dose (days)** | 31 days                           | 10 days                           |
| **Vaccine mechanism**  | mRNA vaccine                      | adenoviral vector vaccine          |
| **Clinical neurological signs and symptoms** | Sensory ataxia                     | Distal paresthesias; facial diplegia; bilateral foot dorsiflexion weakness; lower limb areflexia; stypsis and difficulty in initiating micturition; neuropathic pain |
| **Serum autoimmunity** | Anti-GQ1b                          | None                              |
| **Cerebrospinal fluid** | Protein: 397 mg/dL                | Protein: 2272 mg/dL               |
|                        | Cells: 0.8/µL                      | Cells: 14.6/µL                    |
|                        | Glucose: 53 mg/dL                  | Glucose: 60 mg/dL                 |
| **Nerve conduction studies (NCS)** | Motor studies**                   | Motor and Sensory studies         |
|                        | Right tibialis: A = 2.2 mV (n.v. > 4), normal DL and CV = 40 ms (n.v. > 44) | Upper and lower limbs routine NCS: within normal limits |
|                        | Left peroneal: A = 1.5 mV (n.v. > 2), DL = 6.7 ms (n.v. > 6.5), CV = 42.2 ms (n.v. > 44) | Late responses                     |
|                        | Sensory antidromic studies        | F-wave left tibialis: 61.2 ms (n.v. > 56) |
|                        | Left radialis: A = 4.6 mV (n.v. > 15), CV 41 ms (n.v. 50), normal DL | F-wave right tibialis: 59.8 ms (n.v. < 56) |
|                        | Right radialis: A = 3.2 mV (n.v. > 15), CV 46.9 (n.v. 50), normal DL | H-reflex: bilaterally absent       |
|                        | Left median (digit 3): A = 4.9 mV (n.v. > 20), CV 41 ms (n.v. 50), normal DL | Blink reflex                        |
|                        | Right median (digit 3): A = 4.6 mV (n.v. > 20), CV 41.8 ms (n.v. 50), normal DL | Absent R1 bilaterally, delayed R2 bilaterally*** |
|                        | Left ulnaris (digit 5): A = 5.5 mV (n.v. > 17), CV 45.5 ms (n.v. 50), normal DL |                                  |
|                        | Right ulnaris (digit 5): A = 2.8 mV (n.v. > 17), CV 47.3 ms (n.v. 50), normal DL |                                  |
|                        | Left suralis: A = 0.78 mV (n.v. > 6), CV 42.3 ms (n.v. 40), normal DL |                                  |
|                        | Right suralis: A = 0.82 mV (n.v. > 6), CV 41.8 ms (n.v. 40), normal DL |                                  |
| **ENMG classification** | AMSAN                             | AIDP                              |
| **mEGOS (at admission)** | 2                                 | 1                                 |
| **range 0–9**           |                                    |                                   |
| **mEGOS (at 1 week)**  | 2                                 | 1                                 |
| **range 0–12**          |                                    |                                   |
| **EGRIS/ICU admission** | 1/No                              | 1/No                              |
| **Therapy**             | ivIG 0.4 g/kg/die for 5 days       | ivIG 0.4 g/kg/die for 5 days      |
| **Hughes disability score (at 3 months)** | 1                                 | 1                                 |
| **range 0–6**           |                                    |                                   |

A amplitude, mV millivolt, DL distal latency, CV conduction velocity, msec milliseconds, n.v. normal values, AMSAN acute motor sensory axonal neuropathy, AIDP acute inflammatory demyelinating polyneuropathy, mEGOS modified erasmus GBS outcome scale, EGRIS erasmus GBS respiratory insufficiency score, ICU intensive care unit, ivIG intravenous immunoglobulins

*Excluding Covid-19 vaccination

**motor studies and their normal reference values refer to distal compound muscle action potentials

***The exam was performed on day 15 from symptoms’ onset
Axonal neuropathy and AMSAN variants have also been described; the suspected pathogenetic mechanism is para-
infectious, anti-ganglioside antibodies (including anti-GM1, GM2, GD1a and GQ1b) have been detected and clinical fea-
tures include a more severe weakness and more frequent need of intensive care unit admission when compared to
GBS not related to Covid-19 [7].

Although a causal relationship cannot be ascertained, in the cases here described, the time interval occurring between
vaccination and symptoms onset and the absence of other preceding triggering events suggests at least a possible link
with the immunization, being the time window in line with the development of an immune-mediated response [8]. We
acknowledge that, since serology for common infectious precipitators of GBS was not performed, we cannot exclude a
preceding asymptomatic infection. However, a hypothetical infective antecedent does not exclude a concomitant role of
vaccination.

There is currently no evidence of an exceeding incidence rate of GBS after Covid-19 vaccine. Nevertheless, while
waiting for population studies, any relevant information should be reported to increase the current knowledge regard-
ing this complication, highlighting its diverse clinical and neurophysiological phenotype in the context of Covid immu-
nization programs. In fact, it cannot be excluded that Covid-19 vaccination may represent a trigger for immune-mediated
polyradiculoneuropathy, similarly to other vaccines.

Funding None.

Availability of data and material Anonymized data are available upon reasonable request.

Declarations

Conflict of interest The authors report no disclosure relevant to the manuscript.

Ethical standards All procedures of the study were performed in accordance with the Helsinki Declaration in its most recently amended version.

Informed consent All the patients expressed their informed consent to the anonymous use of their clinical data.

References

1. Uncini A, Kuwabara S (2012) Electrodiagnostic criteria for
Guillain-Barré syndrome: a critical revision and the need for an
update. Clin Neurophysiol 123:1487–1495. https://doi.org/10.
1016/j.clinph.2012.01.025
2. Sejvar JJ, Kohl KS, Gidudu J et al (2011) Guillain-Barré syn-
drome and Fisher syndrome: case definitions and guidelines for
collection, analysis, and presentation of immunization safety data.
Vaccine 29(3):599–612. https://doi.org/10.1016/j.vaccine.2010.
06.003
3. Loza AM, Holroyd KB, Johnson SA, Pilgrim DM, Amato AA
(2021) Guillain-Barré syndrome in the placebo and active arms
of a COVID-19 vaccine clinical trial: temporal associations do
not imply causality. Neurology. https://doi.org/10.1212/wnl.00000
0000011881
4. Waheed S, Bayas A, Hindi F, Rizvi Z, Espinosa PS (2021) Neu-
rological complications of COVID-19: Guillain-Barre syndrome
following Pfizer COVID-19 vaccine. Cureus. https://doi.org/10.
7759/cureus.13426
5. Patel SU, Khurram R, Lakhani A, Quirk B (2021) Guillain-Barre
syndrome following the first dose of the chimpanzee adenovi-
rus-vectored COVID-19 vaccine, ChAdOx1. BMJ Case Rep
14(4):e242956. https://doi.org/10.1136/bcr-2021-242956
6. Lunn MP, Cornblath DR, Jacobs BC et al (2021) COVID-19 vac-
cine and Guillain-Barré syndrome: let’s not leap to associations.
Brain 144(2):357–360. https://doi.org/10.1093/brain/awaa444
7. Koike H, Chiba A, Katsuno M (2021) Emerging infection, vac-
cination, and Guillain-Barré syndrome: a review. Neurol Ther.
https://doi.org/10.1007/s40120-021-00261-4
8. Van den Berg B, Walgaard C, Drenthen J, Fokke C, Jacobs BC,
van Doorn PA (2014) Guillain-Barré syndrome: pathogenesis,
diagnosis, treatment and prognosis. Nat Rev Neurol 10(8):469–
482. https://doi.org/10.1038/nrneurol.2014.121

Publisher’s Note Springer Nature remains neutral with regard to jurisdic-
tional claims in published maps and institutional affiliations.